Registry of Sarcoidosis Associated Pulmonary Hypertension (RESAPH)

This study is currently recruiting participants.
Verified December 2013 by University of Cincinnati
Sponsor:
Collaborator:
The Cleveland Clinic
Information provided by (Responsible Party):
Robert P Baughman, University of Cincinnati
ClinicalTrials.gov Identifier:
NCT01467791
First received: November 4, 2011
Last updated: December 9, 2013
Last verified: December 2013

November 4, 2011
December 9, 2013
November 2011
January 2015   (final data collection date for primary outcome measure)
Survival [ Time Frame: 4 years ] [ Designated as safety issue: No ]
Mortality during time of study
Same as current
Complete list of historical versions of study NCT01467791 on ClinicalTrials.gov Archive Site
Disease management [ Time Frame: 4 years ] [ Designated as safety issue: No ]
Examine initial and follow up management
Same as current
Not Provided
Not Provided
 
Registry of Sarcoidosis Associated Pulmonary Hypertension (RESAPH)
Registry of Sarcoidosis Associated Pulmonary Hypertension (RESAPH)

Registry to follow patients with sarcoidosis associated pulmonary hypertension

This is a multi center registry of sarcoidosis associated pulmonary hypertension (SAPH). With this registry, the investigators will characterize the demographics, clinical course, hemodynamics, pulmonary physiology, and disease management of sarcoidosis associated pulmonary hypertension on the United States. The investigators will also compare these features to non-US sites.

Observational
Observational Model: Case-Only
Time Perspective: Prospective
Not Provided
Retention:   Samples Without DNA
Description:

Serum samples

Non-Probability Sample

Patients with sarcoidosis associated pulmonary hypertension

  • Sarcoidosis
  • Pulmonary Hypertension
Other: Observation
Observe patients
Patients
All patients with sarcoidosis associated pulmonary hypertension
Intervention: Other: Observation
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
300
January 2016
January 2015   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients with sarcoidosis as defined by the ATS/WASOG statement
  • Patients with pulmonary hypertension as confirmed by right heart catheterization
  • Patients willing to provide written informed consent

Exclusion Criteria:

  • Unwillingness to provide assurance that they will complete the follow up visits for the study
Both
18 Years and older
No
Contact: Robert P Baughman, MD 513-584-5225 bob.baughman@uc.edu
Contact: Rebecca Ingledue 513-584-6252
United States
 
NCT01467791
RESAPH 1
No
Robert P Baughman, University of Cincinnati
University of Cincinnati
The Cleveland Clinic
Study Chair: Robert P Baughman, MD University of Cincinnati
University of Cincinnati
December 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP